Showing posts with label green. Show all posts
Showing posts with label green. Show all posts

Monday, 5 August 2013

Revealing the gene network for producing the toxin in green potatoes may help improve crops

Main Category: Water - Air Quality / Agriculture
Article Date: 04 Aug 2013 - 0:00 PDT Current ratings for:
Revealing the gene network for producing the toxin in green potatoes may help improve crops
not yet ratednot yet rated

In 1924, Science magazine reported on a fatal case of potato poisoning: James B. Matheney of Vandalia, Illinois, had gathered about one and a half bushels of tubers, which had turned green due to sunlight exposure. Two days after eating the potatoes, most of his family - wife, two daughters and four sons - showed symptoms of poisoning; the only exceptions were James himself, who didn't eat the potatoes, and a breast-fed baby boy. His wife, aged 45, died a week later, followed by their 16-year-old daughter. The other five members of the family recovered.

Although such fatalities are rare among human beings, farm animals often get sick or die after eating green potatoes. Symptoms include damage to the digestive system as well as loss of sensation, hallucinations and other neurological disturbances. Death can be caused by a disruption of the heart beat. The culprits are the toxic substances solanine and chaconine; their concentration rises sharply with exposure to light or during sprouting, and they protect the tubers from insects and disease.

Solanine and chaconine belong to the large family of glycoalkaloids, which includes thousands of toxins found in small amounts in other edible plants, including tomatoes and eggplant. These substances have been known for over 200 years, but only recently has Prof. Asaph Aharoni of the Plant Sciences Department begun to unravel how they are produced in plants. He and his team have mapped out the biochemical pathway responsible for manufacturing glycoalkaloids from cholesterol. Their findings will facilitate the breeding of toxin-free crops and the development of new crop varieties from wild strains that contain such large amounts of glycoalkaloids, they are currently considered inedible. On the other hand, causing plants to produce glycoalkaloids if they don't do so naturally or increasing their glycoalkaloid content can help protect them against disease.

Two years ago, in research reported in The Plant Cell, the scientists identified the first gene in the chain of reactions that leads to the production of glycoalkaloids. In a new study published recently in Science, they have now managed to identify nine other genes in the chain by using the original gene as a marker and comparing gene expression patterns in different parts of tomatoes and potatoes. Disrupting the activity of one of these genes, they found, prevented the accumulation of glycoalkaloids in potato tubers and tomatoes. The team then revealed the function of each of the genes and outlined the entire pathway, consisting of ten stages, in which cholesterol molecules turn into glycoalkaloids.

An analysis of the findings produced an intriguing insight: Most of the genes involved are grouped on chromosome 7 of the potato and tomato genome. Such grouping apparently prevents the plants from passing on to their offspring an incomplete glycoalkaloid pathway, which can result in the manufacture of chemicals harmful to the plants.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our water - air quality / agriculture section for the latest news on this subject.

The research was conducted by postdoctoral fellow Dr. Maxim Itkin, who worked with Dr. Uwe Heinig, Dr. Oren Tzfadia, Pablo D. Cardenas, Dr. Samuel Bocobza, Dr. Sergey Malitsky and Dr. Ilana Rogachev of Prof. Aharoni’s lab; as well as Dr. Tamar Unger of the Israel Structural Proteomics Center at the Weizmann Institute, and scientists from the National Chemical Laboratory in Pune, India, the Hebrew University of Jerusalem and the Wageningen University, the Netherlands.

Prof. Asaph Aharoni's research is supported by the Clore Center for Biological Physics; the Kahn Family Research Center for Systems Biology of the Human Cell; the Tom and Sondra Rykoff Family Foundation; Roberto and Renata Ruhman, Brazil; the Adelis Foundation; the Leona M. and Harry B. Helmsley Charitable Trust; the Minna James Heineman Stiftung; and the Raymond Burton Plant Genome Research Fund. Prof. Aharoni is the incumbent of the Peter J. Cohn Professorial Chair.

Weizmann Institute of Science

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Weizmann Institute of Science. "Revealing the gene network for producing the toxin in green potatoes may help improve crops." Medical News Today. MediLexicon, Intl., 4 Aug. 2013. Web.
5 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Revealing the gene network for producing the toxin in green potatoes may help improve crops'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Monday, 29 July 2013

NICE gives green light to treatment for wet AMD in final guidance

Main Category: Eye Health / Blindness
Article Date: 26 Jul 2013 - 2:00 PDT Current ratings for:
NICE gives green light to treatment for wet AMD in final guidance
not yet rated4 stars

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending aflibercept solution for injection as an option for treating wet age-related macular degeneration (AMD).

Wet AMD is an eye condition that affects the macula (a tiny part of the retina at the back of the eye). AMD causes problems with central vision - for example, straight lines may appear wavy and blind spots may develop in the field of vision.

Macular degeneration is diagnosed as either dry (non-neovascular) or wet (neovascular). Neovascular refers to growth of new blood vessels in an area, such as the macula, where they are not supposed to be.

There are an estimated 26,000 new cases of wet AMD in the UK each year. Risk factors include increasing age, cigarette smoking (smokers having a 3.6 times greater risk of developing age-related macular degeneration compared with people who have never smoked), and exposure to high levels of UV light. It is also more common in women than men [i].

Aflibercept is recommended as an option for treating wet age related macular degeneration only if: it is used in accordance with the recommendations for ranibizumab in NICE technology appraisal guidance 155 [ii] (re-issued in May 2012), and the manufacturer provides aflibercept solution for injection to the NHS under the terms agreed with the Department of Health as part of a patient access scheme.

Professor Carole Longson, Health Technology Evaluation Centre Director at NICE said: "Wet AMD can have a significant impact on vision, independence and quality of life. Today's guidance, which comes soon after aflibercept received its licence, provides healthcare professionals with clear advice on where and when this treatment can add value as another treatment option for those affected by this distressing condition. "

This is NICE's final guidance on this technology and now replaces local recommendations across the country.

The guidance is available on the NICE website.People currently receiving aflibercept solution for injection whose disease does not meet the criteria detailed above should be able to continue treatment until they and their clinician consider it appropriate to stop.Aflibercept solution for injection (Eylea, Bayer Pharma) is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF-A, VEGF-B, and the placental growth factor. Aflibercept solution for injection prevents these factors from stimulating the growth of the fragile and permeable new blood vessels associated with wet age-related macular degeneration. Aflibercept solution for injection has a UK marketing authorisation 'for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD)'.The summary of product characteristics states that the recommended dose for aflibercept is 2 mg and that treatment should be given monthly for 3 consecutive 2 mg doses, followed by 1 injection every 2 months. Each 100 microlitre vial contains 4 mg of aflibercept. Aflibercept solution for injection must only be administered by a qualified doctor experienced in administering intravitreal injections. The summary of product characteristics also states that there is no need for monitoring between injections. After the first 12 months of treatment, the treatment interval may be extended based on visual and anatomic outcomes. In this case, the schedule for monitoring should be determined by the treating doctor.The list price of aflibercept 40 mg/ml solution for injection is £816 per 100-microlitre vial (excluding VAT; 'British national formulary' [BNF] edition 52).The Committee noted that its preferred analyses incorporated the confidential discount to the list price of aflibercept and a range of discounts (from 0 to 50%) to the list price of ranibizumab. It also noted that, when discounts to the list price of ranibizumab ranged from 0 to 45%, aflibercept had lower costs and quality-adjusted life years (QALYs) than ranibizumab, which resulted in ICERs for aflibercept compared with ranibizumab ranging from £1,692,500 to £16,700 saved per QALY lost and that, when a 50% discount was applied to the list price of ranibizumab, aflibercept was dominated by ranibizumab in both the worse-seeing eye and better-seeing eye model. However, the Committee was aware that, in both the manufacturer's and the ERG's analyses, the differences in total costs and QALYs were very small. The Committee therefore concluded that aflibercept could be recommended as a cost effective use of NHS resources if ranibizumab would otherwise be the treatment used.The independent Appraisal Committee decided that an appraisal consultation document (ACD) was not needed for this appraisal, so the recommendations went straight to a final appraisal determination (FAD). This happens when the Committee recommends a treatment in line with its licensed indication.The manufacturer of aflibercept has agreed a patient access scheme with the Department of Health. This involves a confidential discount applied to the list price of aflibercept solution for injection. The level of the discount is commercial-in-confidence.NICE technology appraisals apply across the NHS in England and Wales.Section 7(6) of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication.Further details on NICE technology appraisals.

Steve Winyard, RNIB's Head of Campaigns, said: "We welcome the news NICE has approved the use of a further drug to treat the biggest cause of sight loss in the UK.

"Not only does it mean patients now have the choice of two different drugs to treat their condition, it also means if they choose the newly approved drug it could mean less visits to the hospital.

"Some people with wet AMD do not respond to the current NICE approved treatment and another option could mean the difference between saving and losing their sight.

"We've recently launched a national campaign encouraging over 50s to spot the signs of wet AMD, which affects about 40,000 people each year and can destroy a person's sight in as little as three months.

"Losing your central vision can have profound consequences with many people unable to carry out basic tasks such as driving, chopping vegetables, or writing a shopping list. However, it doesn't have to be this way and people should not be losing their sight unnecessarily when there's treatment available."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our eye health / blindness section for the latest news on this subject.

Related NICE guidance

Published

NICE & RNIB

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

NICE, RNIB &. "NICE gives green light to treatment for wet AMD in final guidance." Medical News Today. MediLexicon, Intl., 26 Jul. 2013. Web.
29 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'NICE gives green light to treatment for wet AMD in final guidance'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here